Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood

Pediatric Blood and Cancer

Volumn 64, Issue 10, 2017, Pages

  Schmäh, Juliane ^a   Fedders, Birthe ^a   Panzer Grümayer, Renate ^b   Fischer, Susanna ^b   Zimmermann, Martin ^c   Dagdan, Elif ^c   Bens, Susanne ^d,e   Schewe, Denis ^a   Moericke, Anja ^a   Alten, Julia ^a   Bleckmann, Kirsten ^a   Siebert, Reiner ^d,e   Schrappe, Martin ^a   Stanulla, Martin ^c   Cario, Gunnar ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

acute lymphoblastic leukemia; CRLF2; IGH CRLF2; P2RY8 CRLF2; prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; JANUS KINASE 2; MESSENGER RNA; PROTEIN; PROTEIN BTG1; PROTEIN CRLF2; PROTEIN IKZF1; PROTEIN RB1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ASPARAGINASE; CRLF2 PROTEIN, HUMAN; CYTOKINE RECEPTOR; DAUNORUBICIN; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; ONCOPROTEIN; P2RY8 PROTEIN, HUMAN; PAX5 PROTEIN, HUMAN; PREDNISONE; PURINERGIC P2Y RECEPTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CHILD; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOAUTOSOMAL REGION; TREATMENT RESPONSE; ADOLESCENT; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; INFANT; METABOLISM; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFANT; MALE; ONCOGENE PROTEINS, FUSION; PAX5 TRANSCRIPTION FACTOR; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RECEPTORS, CYTOKINE; RECEPTORS, PURINERGIC P2Y; VINCRISTINE;

EID: 85017147206     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26539     Document Type: Article

References (22)

1. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–3214.
2. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771–782.
3. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243–1246.
4. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688–2698.
5. Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012;26(10):2245–2253.
6. Morak M, Attarbaschi A, Fischer S, et al. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL. Blood. 2012;120(26):5134–5142.
7. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26):5393–5397.
8. Yano M, Imamura T, Asai D, et al. An overall characterization of pediatric acute lymphoblastic leukemia with 2 overexpression. Genes Chromosomes Cancer. 2014;53(10):815–823.
9. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012;119(15):3512–3522.
10. Palmi C, Savino AM, Silvestri D, et al. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget. 2016;7(37):59260–59272.
11. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006–1017.
12. Martin-Subero JI, Harder L, Gesk S, et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer. 2002;98(3):470–474.
13. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8(2):141–151.
14. Mann HB, Whitney DR. On a test of whether one of 2 random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1):50–60.
15. Palmi C, Silvestri D, Bronzini I, et al. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Blood. 2014;124(21).
16. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265–284.
17. Tsai AG, Yoda A, Weinstock DM, Lieber MR. t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. Blood. 2010;116(11):1993–1994.
18. Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 2008;135(6):1130–1142.
19. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110–114.
20. Kitagawa Y, Inoue K, Sasaki S, et al. Prevalent involvement of illegitimate V(D)J recombination in chromosome 9p21 deletions in lymphoid leukemia. J Biol Chem. 2002;277(48):46289–46297.
21. Waanders E, Scheijen B, van der Meer LT, et al. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet. 2012;8(2):e1002533.
22. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. Semin Diagn Pathol. 2012;29(1):2–11.